Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 14/20 | 0.67 |
| ▸ | ABCC1 | P33527 | 13/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701487 | 0.87 | ABCB1 (0.59) | ABCB1ABCC1NPC1MAPTMAPK1 | |
| SCHEMBL16701866 | 0.85 | MAPT (0.52) | MAPTHSP90AA1HSP90AB1 | |
| SCHEMBL23969920 | 0.85 | ABCB1 (0.56) | ABCB1ABCC1NPC1MAPTMAPK1 | |
| SCHEMBL16701809 | 0.84 | HSP90AA1 (0.59) | ABCB1ABCC1NPC1MAPTMAPK1 | |
| SCHEMBL16701391 | 0.82 | PLAU (0.65) | NPC1MAPK1RAB9ASMN1; SMN2HSP90AA1 | |
| SCHEMBL16180113 | 0.80 | ABCB1 (1.00) | ABCB1ABCC1 | |
| SCHEMBL16701548 | 0.78 | TRPV1 (0.63) | NPC1RAB9ASMN1; SMN2HSP90AA1HSP90AB1 | |
| SCHEMBL16701553 | 0.78 | MEN1 (0.62) | NPC1MAPTRAB9ASMN1; SMN2HSP90AA1 | |
| SCHEMBL16702332 | 0.76 | HSP90AA1 (0.58) | ABCB1MAPTHSP90AA1HSP90AB1 | |
| SCHEMBL16180282 | 0.76 | ABCB1 (1.00) | ABCB1ABCC1NPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066072-B1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIV KANSAS (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIVERSITY OF KANSAS (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3066072-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | The University of Kansas (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
| US-8692018-B2 | Application of iridium complexes in asymmetric catalytic hydrogenation of unsaturated carboxylic acids | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2014-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | ABCB1 55/4885ABCC1 220/4885NPC1 1414/4885 |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | ABCB1 55/4885ABCC1 220/4885NPC1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.